{
  "emaEpar": [],
  "fdaDrugLabel": [],
  "id": "Sodium_Butyrate",
  "nciThesaurus": {
    "casRegistry": "156-54-7",
    "chebiId": "CHEBI:64103",
    "chemicalFormula": "C4H7O2.Na",
    "definition": "The sodium salt of butyrate with potential antineoplastic activity. Butyrate, a short chain fatty acid, competitively binds to the zinc sites of class I and II histone deacetylases (HDACs). This binding affects hyperacetylation of histones, resulting in a modified DNA conformation, which subsequently leads to the uncoiling or relaxing of chromatin. Enhanced accessibility of chromatin to transcription-regulatory complexes leads to increased transcriptional activation of various epigenetically suppressed genes. Butyrate, a HDAC inhibitor, induces cell cycle arrest in G1 or G2/M and also increases the expression of other genes and proteins involved in cellular differentiation and apoptotic signaling.",
    "fdaUniiCode": "8RAS91C36W",
    "identifier": "C2337",
    "preferredName": "Sodium Butyrate",
    "semanticType": "Organic Chemical",
    "subclassOf": [
      "C1946"
    ],
    "synonyms": [
      "Butyrate",
      "Butyrate sodium",
      "Butyric Acid, Sodium Salt",
      "SODIUM BUTYRATE",
      "Sodium Butyrate",
      "Sodium butanoate",
      "Sodium butyrate",
      "butyric acid, sodium salt",
      "sodium butanoate"
    ]
  }
}